AC Immune
ACIU Healthcare Biotechnology
AC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024. In the quarter to June 2026, revenue grew 29.7%, EPS grew 9.52% and free cash flow grew 4.66%, each against the same quarter a year earlier.
Follow ACIU
AC Immune (ACIU) EV/Sales
As of 16 October 2026, AC Immune (ACIU) trades at a EV/Sales of 31.3×. Over the past ten years it has ranged from −0.3× (April 2025) to 117× (December 2017); the current reading is higher than 81% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 48.3× | 1,695.76% |
| FY2024 | 2.7× | (93.93%) |
| FY2023 | 44.4× | 385.70% |
| FY2022 | 9.1× | 12.90% |
| FY2020 | 8.1× | 188.24% |
| FY2019 | 2.8× | (94.76%) |
| FY2018 | 53.6× | 73.48% |
| FY2017 | 30.9× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 38.9× | (19.44%) |
| Dec 2025 | 48.3× | 42.44% |
| Sep 2025 | 33.9× | 2,024.65% |
| Jun 2025 | 1.6× | 81.67% |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | 0.4× |
| XFOR X4 Pharmaceuticals, Inc. compare | 12.4× |
| LCTX Lineage Cell Therapeutics, Inc. compare | 14.8× |
| ACIU AC Immune | 31.3× |
| SABS SAB Biotherapeutics, Inc. compare | 62.8× |
| IKT Inhibikase Therapeutics, Inc. compare | 495× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)